Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma|HCC|Liver Cancer
BIOLOGICAL: hepcortespenlisimut-L|BIOLOGICAL: Placebo
changes in plasma AFP, Changes in plasma AFP levels at monthly intervals, 3 months
CT scan, changes in tumor size/mumber at 3 months compared to baseline, 3 months
adverse effects, evaluation of adverse effects if any, 3 months
Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma. The results will be compared to placebo. The trial duration is 3 months and will consist of one stage with baseline laboratory evaluation including AFP levels with follow-up at monthly intervals. In addition pre-entry abdominal CT scan and end-study CT scan will be preformed. The clinical evaluation will be quantified according to special performance questionnaire.